Key statistics
On Friday, Cellectar Biosciences Inc (CLRB:NAQ) closed at 3.25, 32.45% above the 52 week low of 2.45 set on Dec 17, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 3.41 |
|---|---|
| High | 3.50 |
| Low | 3.20 |
| Bid | 3.06 |
| Offer | 3.68 |
| Previous close | 3.51 |
| Average volume | 22.21k |
|---|---|
| Shares outstanding | 4.24m |
| Free float | 4.07m |
| P/E (TTM) | -- |
| Market cap | 13.76m USD |
| EPS (TTM) | -10.78 USD |
Data delayed at least 15 minutes, as of Feb 27 2026 20:59 GMT.
More ▼
- Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
- Cellectar Biosciences Expands Global Intellectual Property Estate
- Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
- Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
- Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
- Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
- Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
- Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
- Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
More ▼
